New analysis from GlobalData spans the growth of the heart failure market across seven major markets including the US, Europe ...

Johnson & Johnson said on Wednesday it has temporarily paused the rollout of its Varipulse heart device in the United States, ...

Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...

The U.S. Food and Drug Administration (FDA) has approved a groundbreaking drug, acoramidis (marketed as Attruby), developed ...

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...